| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a23a7e20fd8968919daca6d47ac689c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28e3113097dd6d28720572e47f2f2407 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 |
| filingDate |
2002-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d3963241cd47f34f834fa47c9755a66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee4d187dd77d296e900b87fe9cfd3585 |
| publicationDate |
2013-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2426723-T3 |
| titleOfInvention |
Granules containing large amount of chemical compound unstable in acidic medium |
| abstract |
Capsules containing granules comprising a main ingredient layer containing lansoprazole or an R isomer thereof in an amount of 14% by weight to 20% by weight based on the total granules, and one or more basic inorganic salts selected from the group consisting of basic magnesium and calcium salts in an amount of 0.2 parts by weight to 0.4 parts by weight based on 1 part by weight of lansoprazole or an R isomer thereof; an intermediate coating layer that is formed on the main ingredient layer; and an enteric coating layer that is formed on the intermediate coating layer, and having an average particle size of 1,000 μm to 2,000 μm measured using a sieving method and calculated based on a half mesh of the corresponding sieves and weight distribution , selected from: (i) capsules from 3 to 5 comprising 30 mg of lansoprazole or an R isomer thereof for one capsule; (ii) capsules No. 4 to 5 comprising 15 mg of lansoprazole per capsule; (iii) capsules No. 1 to 3 comprising 60 mg of lansoprazole or an R isomer thereof per one capsule; and (iv) capsules No. 2 to 4 comprising 40 mg of an R isomer of lansoprazole per capsule. |
| priorityDate |
2001-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |